Avalo Therapeutics's three largest insider shareholders as of September 29, 2026 are Garry Arthur Neil (Chief Executive Officer, 190.31K shares), Mittie Doyle (Chief Medical Officer, 51.78K shares), Christopher Ryan Sullivan (Chief Financial Officer, 39.90K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Garry Arthur Neil | Chief Executive Officer | 190,314 | 0 | 190,314 | 49.2% | 26 May, 2026 |
| 2 | Mittie Doyle | Chief Medical Officer | 51,776 | 0 | 51,776 | 13.4% | 01 Sep, 2026 |
| 3 | Christopher Ryan Sullivan | Chief Financial Officer | 39,900 | 0 | 39,900 | 10.3% | 18 Sep, 2026 |
| 4 | Jennifer Riley | Chief Strategy Officer | 37,041 | 0 | 37,041 | 9.6% | 12 Aug, 2026 |
| 5 | Paul Varki | Chief Legal Officer | 32,576 | 0 | 32,576 | 8.4% | 12 Jun, 2026 |
| 6 | Gilla Kaplan | Director | 6,333 | 0 | 6,333 | 1.6% | 31 Mar, 2026 |
| 7 | Aaron Kantoff | Director | 6,333 | 0 | 6,333 | 1.6% | 31 Mar, 2026 |
| 8 | Samantha Truex | Director | 6,333 | 0 | 6,333 | 1.6% | 31 Mar, 2026 |
| 9 | June Sherie Almenoff | Director | 3,167 | 0 | 3,167 | 0.8% | 01 Apr, 2025 |
| 10 | Jonathan Goldman | Director | 3,166 | 0 | 3,166 | 0.8% | 31 Mar, 2026 |
| 11 | Mitchell Chan | Director | 3,166 | 0 | 3,166 | 0.8% | 07 May, 2026 |
| 12 | James Archie Jr Harrell | Chief Commercial Officer | 3,064 | 0 | 3,064 | 0.8% | 14 Dec, 2021 |
| 13 | H Jeffrey Wilkins | Chief Medical Officer | 2,781 | 0 | 2,781 | 0.7% | 14 Dec, 2021 |
| 14 | Capital Management Ltd. Caissa | TenPercentOwner | 0 | 481 | 481 | 0.1% | 30 May, 2023 |
| 15 | Schond L. Greenway | Cfo | 324 | 0 | 324 | 0.1% | 14 Dec, 2021 |
| 16 | Capital, Llc Armistice | TenPercentOwner | 0 | 254 | 254 | 0.1% | 28 Jun, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 16 Sep, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Acquired M | 12,394 | $9.88 | $122.45K | 52,294 | Direct |
| 16 Sep, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Disposed S | 12,394 | $16.33 | $202.44K | 39,900 | Direct |
| 16 Sep, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Disposed M | 12,394 | $0.00 | $0 | 83,848 | Direct |
| 10 Sep, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Acquired M | 10,185 | $8.04 | $81.89K | 50,085 | Direct |
| 10 Sep, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Disposed S | 10,185 | $17.62 | $179.46K | 39,900 | Direct |
| 10 Sep, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Disposed M | 10,185 | $0.00 | $0 | 105,815 | Direct |
| 28 Aug, 2026 | Mittie Doyle | Chief Medical Officer | Acquired M | 679 | $8.04 | $5.46K | 52,455 | Direct |
| 28 Aug, 2026 | Mittie Doyle | Chief Medical Officer | Disposed S | 679 | $20.00 | $13.58K | 51,776 | Direct |
| 28 Aug, 2026 | Mittie Doyle | Chief Medical Officer | Disposed M | 679 | $0.00 | $0 | 113,734 | Direct |
| 17 Aug, 2026 | Mittie Doyle | Chief Medical Officer | Acquired M | 1,000 | $12.65 | $12.65K | 52,776 | Direct |
| 17 Aug, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Acquired M | 37,945 | $9.88 | $374.90K | 78,718 | Direct |
| 17 Aug, 2026 | Mittie Doyle | Chief Medical Officer | Disposed S | 1,000 | $20.00 | $20.00K | 51,776 | Direct |
| 17 Aug, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Acquired M | 2,876 | $9.88 | $28.41K | 81,594 | Direct |
| 17 Aug, 2026 | Mittie Doyle | Chief Medical Officer | Disposed M | 1,000 | $0.00 | $0 | 123,750 | Direct |
| 17 Aug, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Disposed S | 37,945 | $19.85 | $753.33K | 43,649 | Direct |
| 17 Aug, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Disposed S | 3,749 | $19.94 | $74.76K | 39,900 | Direct |
| 18 Aug, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Acquired M | 31,031 | $9.88 | $306.59K | 70,931 | Direct |
| 18 Aug, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Disposed S | 31,031 | $20.05 | $622.32K | 39,900 | Direct |
| 17 Aug, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Disposed M | 37,945 | $0.00 | $0 | 130,149 | Direct |
| 17 Aug, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Disposed M | 2,876 | $0.00 | $0 | 127,273 | Direct |